Revisi per 13 Juli 2021 06.41 sunting HsfBot (bicara \| kontrib) Bot 1.172.581 suntingan k Bot: +{{Authority control}} Tag: PAWS [2.1] ← Revisi sebelumnya		Revisi per 27 September 2022 02.28 sunting balikkan AABot (bicara \| kontrib) Bot, Pengecualian blokir IP 914.166 suntingan k ~ref Tag: PAWS [2.1] Revisi selanjutnya →
Baris 6: <!--Chemical data-->\|C=19\|H=15\|Cl=1\|N=2\|O=4\|molecular_weight=370.786 g/mol\|smiles=Clc1ccc(cc1)C(=O)NC(C(=O)O)CC2=CC(=O)Nc3ccccc32\|StdInChI_Ref={{stdinchicite\|correct\|chemspider}}\|StdInChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)\|StdInChIKey_Ref={{stdinchicite\|correct\|chemspider}}\|StdInChIKey=ALLWOAVDORUJLA-UHFFFAOYSA-N}} '''Rebamipide''' adalah turunan [[asam amino]] dari 2-(1''H'')-quinolinon yang digunakan untuk perlindungan [[Membran mukosa\|mukosa]], <ref>{{Cite journal\|last=Arakawa\|first=T.\|last2=Kobayashi\|first2=K.\|last3=Yoshikawa\|first3=T.\|last4=Tarnawski\|first4=A.\|date=1998\|title=Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing\|url=https://www.ncbi.nlm.nih.gov/pubmed/9753220\|journal=Digestive Diseases and Sciences\|volume=43\|issue=9 Suppl\|pages=5S–13S\|issn=0163-2116\|pmid=9753220}}</ref> penyembuhan [[Ulkus peptikum\|tukak lambung]] (ulkus peptikum), dan pengobatan maag ([[Maag\|gastritis)]].<ref>{{Cite journal\|last=Arakawa\|first=T.\|last2=Watanabe\|first2=T.\|last3=Fukuda\|first3=T.\|last4=Yamasaki\|first4=K.\|last5=Kobayashi\|first5=K.\|date=1995\|title=Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine\|url=https://www.ncbi.nlm.nih.gov/pubmed/7587834\|journal=Digestive Diseases and Sciences\|volume=40\|issue=11\|pages=2469–2472\|issn=0163-2116\|pmid=7587834}}</ref> Obat bekerja dengan meningkatkan pertahanan mukosa, membersihkan [[Radikal bebas\|radikal]] bebas,<ref>{{Cite journal\|last=Takumida\|first=Masaya\|last2=Anniko\|first2=Matti\|date=2009\|title=Radical scavengers for elderly patients with age-related hearing loss\|url=https://www.ncbi.nlm.nih.gov/pubmed/18607930\|journal=Acta Oto-Laryngologica\|volume=129\|issue=1\|pages=36–44\|doi=10.1080/00016480802008215\|issn=1651-2251\|pmid=18607930}}</ref> dan mengaktifkan gen penyandi [[siklooksigenase]]-2 secara sementara.<ref>{{Cite journal\|last=Tarnawski\|first=A. S.\|last2=Chai\|first2=J.\|last3=Pai\|first3=R.\|last4=Chiou\|first4=S. K.\|date=2004\|title=Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?\|url=https://www.ncbi.nlm.nih.gov/pubmed/15104358\|journal=Digestive Diseases and Sciences\|volume=49\|issue=2\|pages=202–209\|issn=0163-2116\|pmid=15104358}}</ref> Rebamipide tersedia di sejumlah negara Asia termasuk [[Jepang]] (dipasarkan sebagai '''Mucosta'''), [[Korea Selatan]], [[Republik Rakyat Tiongkok\|Cina]],<ref> [https://www.drugs.com/international/rebamipide.html drugs.com] </ref> [[India]] (dipasarkan sebagai '''Rebagen'''), dan Rusia (dipasarkan sebagai '''Rebagit)'''.<ref>{{Cite web\|url=http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bb32bbf8-84de-45c9-8ccf-df0789843d66&t=\|title=Russian State Register of Medicines. Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets\|language=Russian\|access-date=10 June 2017}}</ref> Obat ini tidak disetujui oleh Badan Pengawasan Obat dan Makanan Amerika Serikat ([[Badan Pengawas Obat dan Makanan Amerika Serikat\|US Food and Drug Administration]]). Peneilitian telah menunjukkan bahwa rebamipide dapat melawan efek merusak [[Obat antiinflamasi nonsteroid\|NSAID]] pada mukosa [[Sistem pencernaan\|saluran pencernaan]],<ref>{{Cite journal\|last=Zhang\|first=Shaoheng\|last2=Qing\|first2=Qing\|last3=Bai\|first3=Yang\|last4=Mao\|first4=Hua\|last5=Zhu\|first5=Wei\|last6=Chen\|first6=Qikui\|last7=Zhang\|first7=Yali\|last8=Chen\|first8=Ye\|date=2013\|title=Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis\|url=https://www.ncbi.nlm.nih.gov/pubmed/23456504\|journal=Digestive Diseases and Sciences\|volume=58\|issue=7\|pages=1991–2000\|doi=10.1007/s10620-013-2606-0\|issn=1573-2568\|pmid=23456504}}</ref> dan baru-baru ini pada usus halus, tetapi tidak untuk kerusakan lambung yang diinduksi naproksen.<ref>{{Cite journal\|last=Gagliano-Jucá\|first=Thiago\|last2=Moreno\|first2=Ronilson A.\|last3=Zaminelli\|first3=Tiago\|last4=Napolitano\|first4=Mauro\|last5=Magalhães\|first5=Antônio Frederico N.\|last6=Carvalhaes\|first6=Aloísio\|last7=Trevisan\|first7=Miriam S.\|last8=Wallace\|first8=John L.\|last9=De Nucci\|first9=Gilberto\|date=2016-06-04\|title=Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial\|url=https://www.ncbi.nlm.nih.gov/pubmed/27259970\|journal=BMC gastroenterology\|volume=16\|issue=1\|pages=58\|doi=10.1186/s12876-016-0472-x\|issn=1471-230X\|pmc=PMC4893238\|pmid=27259970}}</ref> Obat juga telah dipelajari untuk pengobatan [[penyakit Behçet]].<ref>{{Cite journal\|year=2003\|title=Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study\|journal=Drugs in R&D\|volume=4\|issue=1\|pages=19–28\|doi=10.2165/00126839-200304010-00002\|pmid=12568631}}</ref> Itu terbukti berhasil mengobati pouchitis dalam studi N-tunggal setelah terapi lini pertama untuk kondisi tersebut tidak berhasil.<ref>http://www.wjgnet.com/1007-9327/12/656.pdf {{Webarchive}}</ref> Beberapa penelitian telah menunjukkan efektivitas pada presbyacusis ([[Ketulian\|gangguan pendengaran]] terkait usia). <ref>{{Cite journal\|last=Takumida\|first=Masaya\|last2=Anniko\|first2=Matti\|date=2005\|title=Radical scavengers: a remedy for presbyacusis. A pilot study\|url=https://www.ncbi.nlm.nih.gov/pubmed/16303676\|journal=Acta Oto-Laryngologica\|volume=125\|issue=12\|pages=1290–1295\|doi=10.1080/00016480510037032\|issn=0001-6489\|pmid=16303676}}</ref> Obat juga telah terbukti mengurangi tanda dan gejala [[Xerophtalmia\|mata kering]] (xerophtalmia) dalam uji coba terkontrol secara acak meskipun ini belum tersedia secara klinis.<ref>{{Cite journal\|last=Kinoshita\|first=S.\|last2=K. Oshiden\|last3=S. Awamura\|last4=H. Suzuki\|last5=N. Nakamichi\|year=2013\|title=A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye\|journal=Ophthalmology\|volume=120\|issue=6\|pages=1158–65\|doi=10.1016/j.ophtha.2012.12.022\|pmid=23490326}}</ref>

Rebamipid: Perbedaan antara revisi